Studies [20,167,168,170] have shown that the inhibition of NLRP3, ASC, Caspase-1, or IL-1β can reduce Aβ deposition, tau pathology, and neuroinflammation, suggesting that targeting these components can mitigate the neurodegenerative processes underlying AD. The gene discussed is MAPT; the disease is Alzheimer disease.